X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
Details:
Derm-Biome’s newly developed compounds far outperformed crisaborole blocking the development of skin inflammation in a mouse model of atopic dermatitis.
Lead Product(s): Crisaborole
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
Padagis's Paragraph IV Abbreviated New Drug Application filing for crisaborole ointment 2%, asserting patents listed in Orange Book for Eucrisa®. Padagis's first-to-file ANDA for generic version of Eucrisa® (crisaborole ointment 2%) for treatment of atopic dermatitis.
Lead Product(s): Crisaborole
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
